Generated by AI
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. BriaCell Therapeutics Corp. is best known for its cell-based oncology programs, including Bria-IMT, a lead therapy being studied for metastatic breast cancer, along with Bria-OTS, a personalized off-the-shelf immunotherapy platform, and Bria-PROS+ for prostate cancer. The company also works on BriaDx, a diagnostic tool designed to support patient selection for its immunotherapy approaches. Its current business centers on advancing cancer treatment candidates through clinical development, with an emphasis on breast cancer and other solid tumors. Based in West Vancouver, Canada, BriaCell Therapeutics Corp. operates within the immuno-oncology segment of the healthcare market, where it develops novel therapeutic and diagnostic assets aimed at improving how cancer is detected and treated.
WebsiteBellevue Centre
West Vancouver, BC, V7T 2X1
Canada
The latest articles about BCTX.
Announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients ...
Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the BriaCell regimenFindings from a prospective pooled analysis of 111 heavily pretreated metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapiesPooled analysis includes patients from mul
Today announced that four abstracts featuring preclinical research from their respective immunotherapy ...
Summary of Nov 12's posts. Generated by AI.
Summary of Aug 24's posts. Generated by AI.
Summary of Aug 24's posts. Generated by AI.
Investors talking about BCTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.